Ohta Shigeru

2021 - 2024 腸内細菌応答による薬物性肝障害の予測とその治療展開

2019 - 2022 Control of uric acid by considering the change xanthine oxidase activity with the circadian rhythm

2018 - 2021 Toxicities and pharmacokinetics of new chemical structures of designer drugs, and their prediction in humans

2018 - 2021 Strategy of personalized drug therapy considering organ crosstalk of drug metabolism and toxicity during liver regeneration

2018 - 2021 基盤研究(B) 2018-2020年度 「危険ドラッグの新規化学構造と毒性・動態相関の解明およびヒトへの影響予測」

2017 - 2020 Epigenetic regulation of sex-specific gene expression and investigation of the effects of environmental chemicals and drugs

2016 - 2019 Screening and application of drugs that facilitate membrane trafficking in order to overcome ER stress-related diseases

2015 - 2019 Neurotoxicity of organotins via nuclear respiratory factor-1 (NRF-1) inhibition

2016 - 2018 Development of neuro and cardiac toxicity models considering disposition and interactions of toxic chemicals

2015 - 2018 Structure-Activity Relationship and Mechanistic Studies on Sodium 4-phenylbutyrate and its derivatives

2016 - 2018 挑戦的萌芽研究 2016-2017年度 「薬毒物の動態特性および薬物間相互作用を考慮した中枢・心臓毒性モデルの構築」 研究代表者;太田茂

2016 - 2017 Structure-toxicity relationship of designer drug having phenethylamine moiety

2014 - 2017 Assessment of toxicity associated with protein degradation of drug-metabolizing enzymes by cehemicals in three-dimensional culture

2014 - 2017 Toxicological effects by disposition of chemicals during development of Xenopus tropicalis

2014 - 2017 基盤研究(B) 2014-2016年度 「3次元培養を用いた化学物質による薬物代謝酵素の分解に伴う毒性変動評価」

2014 - 2016 Prediction of metabolism and metabolome analysis of designer drugs using humanized liver mice

2013 - 2016 Estimation for the adequate dose of nicotine by using the ratio of the metabolites in urine

2014 - 2016 挑戦的萌芽研究 2014-2015年度 「ヒト型肝臓動物モデルを利用したデザイナードラッグのメタボローム解析と体内動態予測」

2012 - 2015 Investigation and model preparation of tropical area-specific endemic neurodegenerative diseases

2011 - 2014 Organotin-induced GluR2 decrease and its in vivo neuronal effects

2011 - 2014 Risk assessment of chemicals using chimeric mice with humanized liver

2011 - 2014 基盤研究(B) 2011-2013年度 「ヒト型肝臓動物モデルを利用した化学物質のヒトリスク評価」

2011 - 2013 挑戦的萌芽研究 2011-2012年度 「創薬におけるヒト型肝臓動物モデルを利用した体内動態の個体間変動予測法」

2011 - 2012 Prediction of interindividual differences of drug metabolism and pharmacokinetics using chimeric mice with humanized liver

2008 - 2011 基盤研究(B) 2008-2010年度 「熱帯風土病パーキンソン病関連疾患の病因に基づく新規モデル動物を利用した治療薬開発」

2008 - 2011 基盤研究(B) 2008-2010年度 「家族性パーキンソン病発症メカニズムを規範とした孤発性パーキンソン病発症機構解析」

2009 - 2011 Study of PPCPs in Eastern Asian countries

2008 - 2010 Pathogenetic mechanism of sporadic Parkinson's disease based on familial Parkinson's disease

2008 - 2010 Drug development using novel animal model based on the pathogenesis of Parkinson' s disease-related disorders

2008 - 2010 Study of environmental pollution by pharmaceuticals and effect of environmental factors on the toxicity.

2007 - 2008 染色体一本鎖テロメア測定によるカリブ海で多発するパーキンソニズムの早期診断

2006 - 2007 Development of anti-Parkinson's disease drugs using P-glycoprotein knockout mice heated with endogenous neurotoxin.

2006 - 2007 Integrated analysis of environmental and genetic factors against Caribbean parkinsonism

2006 - 2007 Formation of Hydroxylated Metabolites Responsible for the Toxicity of Brominated Flame Retardants and Thyroid Hormone Disrupting Action

2005 - 2006 Pharmaceuticals in hospital sewages and their toxicities to ecosystem

2005 - 2005 薬学実務実習開始前の臨床能力評価方法に関する調査研究

2004 - 2005 Parkinsonism-inducing mechanism by endogenous multifunctional neurotoxins in the brain

2004 - 2005 Elucidation of the cause of Caribbean parkinsonism and prevention in other area

2004 - 2005 Thyroid hormone-disrupting activity of brominated retardants and hydroxylated PCBs

2002 - 2004 Development and pharmacological analysis of therapeutic drugs for conformation diseases and prion diseases

2002 - 2003 Development of anti-parkinsonian drug using structure-activity relationship

2002 - 2003 Detection of parkinsonism causing substances in French West Indies

2001 - 2002 Metabolic activation of endocrine-disruptors in animal body

2001 - 2002 Effect of Dioxin and Endocrine disrupters on Adrenal Hormone

2000 - 2001 Research for the Parkinson's disease related proteins using endogenous neurotoxins

1999 - 2000 Metabolism and endocrine disrupting action of environmental pollutants

1997 - 2000 遺伝的素因と環境因子の相互作用による神経細胞死

1998 - 1999 Investigation of Parkinson's disease causing substances

1998 - 1999 Early markers of Parkinson's disease

1997 - 1999 SMART MOLECULAR DESIGN OF METAL COMPLEXES WITH BIOLOGICAL ACTIVITIES

1997 - 1998 脳スライス培養系における神経回路形成と内因性物質の神経毒性に関する研究

1997 - 1997 脳細胞の選択的死と機能分子

1997 - 1997 生理活性種一酸化窒素のバイオイメージング法の開発と生体系への応用

1996 - 1996 内在性パーキンソニズム防御物質1-メチル-TIQの合成酵素探索と代謝動態

1996 - 1996 外因による脳神経細胞死のモデルとその応用

1994 - 1994 覚醒剤拮抗薬4-フェニルテトラヒドロイソキノリンの応用研究

1993 - 1993 神経毒性を有する覚醒剤由来新規代謝物及び類縁体の構造活性相関

1993 - 1993 脳細胞の選択的死と機能分子

1992 - 1993 Development and Biological Application of Highly Sensitive Detection Method for Endothelial Relaxing Factor : NO

1992 - 1993 神経細胞死のメカニズムと防御に関する研究

1991 - 1993 Development of anti-parkinsonism agent related to endogenous amines as pharmacophore

1992 - 1992 4-フェニルテトラヒドロイソキノリンの覚醒剤拮抗作用に関する研究

1990 - 1992 Application of Chemical Cytochrome P-450 Model System to Studies on Drug Metabolism.

1991 - 1991 芳香族アミノ酸の生体内環化縮合反応による中枢神経系作用の発現

1990 - 1990 覚醒剤の構造ー活性相関およびその拮抗薬に関する研究

1990 - 1990 フェネルアミン類(ノルエピネフリン・MDMA等)の生体内閉環反応による活性変換

1990 - 1990 ス-パ-オキサイドによる遺伝子損傷とその有機化学的解析

1989 - 1989 チオレ-ト軸配位子効果に重点をおいたp・450の構造・機能特性の分子論的解析

1989 - 1989 パ-キンソン病発症関連物質テトラヒドロイソキノリン類の生体内挙動及び発症機構

1989 - 1989 覚醒剤の立体構造と薬理作用 覚醒剤の拮抗薬の探索

1989 - 1989 ス-パ-オキシド(O_2^〓)の有機合成化学への応用ー新規有機酸化反応の開発ー

1987 - 1989 Studies on the Development of Novel Anti-inflammatory Based on Superoxide Dismutase Activity

1988 - 1988 覚醒剤の立体構造と薬理作用の相関

1987 - 1987 生体内フェニルエチルアミンの役割に関する薬理学的研究(覚醒剤作用との関連性)

1984 - 1986 Studies on the Enzyme Reaction Mechanism of Cytochrome P450